Business
Mironid raises USD 46m to advance first-in-class ADPKD therapy
Glasgow-based Mironid has raised USD 46 million in a Series B round to advance the clinical development of its lead small molecule candidate for autosomal...
Alteogen lands third ALT-B4 license deal with undisclosed partner, up to USD 365m total
South Korea-based Alteogen Inc. (KOSDAQ: 196170) has signed an exclusive license agreement with an undisclosed global pharmaceutical company, granting...
Marengo nominates first TriSTAR candidate under USD 1.2b Ipsen collaboration
Marengo Therapeutics has nominated its first development candidate under its TriSTAR collaboration with Ipsen (Euronext: IPN), triggering milestone payments...
Adneuris licenses cebranopadol to Maruishi in second ex-US deal within four weeks
Adneuris Therapeutics has granted Japan-based Maruishi Pharmaceutical Co., Ltd. an exclusive license to develop and commercialize cebranopadol, a...
Gilead Q2'26: BIC/LEN nears approval as weekly HIV pipeline expands
Gilead Sciences Q2 2026 earnings call, held on August 4, 2026, centered on three near-term binary events — an FDA decision on bictegravir plus lenacapavir...
Amgen Q2'26: MariTide strategy sharpens as AMG 513 exits pipeline
Amgen (Nasdaq: AMGN) held its Q2 2026 earnings call on August 4, 2026, with the most consequential pipeline disclosures centered on three decisions: the...
Chugai signs up for Phylo's Biomni Lab agentic AI drug discovery platform
Phylo, Inc. has announced a collaboration with Chugai Pharmaceutical Co., Ltd. (Tokyo Stock Exchange: 4519) to deploy Biomni Lab, Phylo's agentic AI...
IQVIA to support Medera's cardiac gene therapy and human organoid platform
IQVIA (NYSE: IQV) and Medera Inc. have announced a collaboration to advance Medera's cardiac gene therapy pipeline and its Novoheart human cardiac organoid...
Grace Therapeutics raises USD 10m to fund manufacturing strategy for NDA resubmission
Princeton, New Jersey-based Grace Therapeutics, Inc. (Nasdaq: GRCE) announced a USD 10 million private placement to fund manufacturing and regulatory work...
Merck Q2'26: Sac-TMT Phase III win prompts rethink of first-line NSCLC strategy
Merck & Co. (NYSE: MRK) held its Q2 2026 earnings call on August 4, 2026, during which the company reported its first positive Phase III readout from the...
Pfizer Q2'26: Mevrometostat, tilrekimig and sigvotatug vedotin shape pipeline outlook
Pfizer (NYSE: PFE) held its Q2 2026 earnings call on August 4, 2026, with three pipeline developments dominating analyst attention: a Q4 readout for the...
Takeda Q1 FY2026: Zasocitinib, TAK-928 and mezagitamab drive pipeline update
Takeda Q1 2026 Earnings Call on July 30, 2026 revealed that zasocitinib has now demonstrated statistical superiority over deucravacitinib (Sotyktu) across...
Daiichi Sankyo Q1 FY2026: Datroway delay, R-DXd uncertainty and CD25 ADC debut
Daiichi Sankyo's Q1 FY2027 earnings call, held on July 31, 2026, surfaced three material pipeline developments: a delayed data readout for Datroway in...
Cirrus adds SERI, Duke-NUS collaboration and extends seed financing
Cambridge, Massachusetts-based Cirrus Therapeutics, Inc., an ocular immunology biotech focused on chronic blinding diseases, has announced an expanded...
Photocure and Asieris clash over USD 11m China milestone for Cevira approval
Norway-based Photocure ASA (OSE: PHO) faces a widened legal dispute with China-based Asieris Pharmaceuticals (SSE: 688176) over a USD 11 million milestone...
The AllSci Brief
Free, systematic R&D and deal news. Daily.